Yüklüyor......
Pioglitazone and cardiovascular risk reduction: time for a second look?
Insulin resistance, a fundamental pathophysiological abnormality in patients with type 2 diabetes, is associated with increased cardiovascular (CV) disease risk. In diabetes management, the macrovascular impact of antihyperglycemic agents that do not improve insulin sensitivity has generally been di...
Kaydedildi:
| Yayımlandı: | Cardiovasc Endocrinol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wolters Kluwer Health
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6768516/ https://ncbi.nlm.nih.gov/pubmed/31646121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000110 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|